Why I only took Olaparib for two years

Olaparib is a poly(ADP-ribose) polymerase, or PARP inhibitor, that works by interfering with the activity of enzymes that repair damaged DNA in cancer cells. Cancers containing BRCA gene mutations already have problems with DNA repair, and PARP inhibitors can make it harder for these cells to survive. For patients with ovarian and breast cancer, treatment with Lynparza is generally recommended for two years.

The efficacy of olaparib is significant in the early stages of treatment, but as time goes by, drug resistance may occur. By limiting the duration of olaparib use, the risk of drug resistance can be reduced and treatment effectiveness improved. Patients with newly diagnosed advanced ovarian cancer (carrying a BRCA gene mutation) who took the targeted drug Lynparza after initial treatment lived three and a half years longer without disease progression compared with placebo. Once a patient's ovarian cancer recurs, it has historically been incurable. Even in advanced stages of cancer, maintenance treatment with olaparib has been shown to help patients achieve sustained remission.

Lynparza The original drug has been launched in China and has entered the scope of Class B medical insurance, but it is only available to patients who meet the indications. The price of each box of 150mg*56 tablets may be around RMB 6,000. There are price differences for drugs of different specifications. There are also Olaparibgeneric drugs produced overseas. The specifications produced by Bangladesh pharmaceutical factories150mg*120 tablets per box may cost around RMB 4,000 (the price may fluctuate due to the exchange rate). Its drug ingredients are basically the same as those of the Olaparib original drug. For more drug information and specific prices, please consult Yaode Medical Consultant.